|
1
|
De Gottardi A, Spahr L,
Ravier-Dall'Antonia F and Hadengue A: Cannabinoid receptor 1 and 2
agonists increase lipid accumulation in hepatocytes. Liver Int.
30:1482–1489. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pai WY, Hsu CC, Lai CY, Chang TZ, Tsai YL
and Her GM: Cannabinoid receptor 1 promotes hepatic lipid
accumulation and lipotoxicity through the induction of SREBP-1c
expression in zebrafish. Transgenic Res. 22:823–838. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Auguet T, Berlanga A, Guiu-Jurado E, Terra
X, Martinez S, Aguilar C, Filiu E, Alibalic A, Sabench F, Hernández
M, et al: Endocannabinoid receptors gene expression in morbidly
obese women with nonalcoholic fatty liver disease. Biomed Res Int.
2014:5025422014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Purohit V, Rapaka R and Shurtleff D: Role
of cannabinoids in the development of fatty liver (Steatosis). AAPS
J. 12:233–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Osei-Hyiaman D, DePetrillo M, Pacher P,
Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L,
Wang L and Kunos G: Endocannabinoid activation at hepatic CB1
receptors stimulates fatty acid synthesis and contributes to
diet-induced obesity. J Clin Invest. 115:1298–1305. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Zhou L, Xiong K, Godlewski G,
Mukhopadhyay B, Tam J, Yin S, Gao P, Shan X, Pickel J, et al:
Hepatic cannabinoid receptor-1 mediates diet-induced insulin
resistance via inhibition of insulin signaling and clearance in
mice. Gastroenterology. 142:1218–1228.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Floreani A, Lazzari R, Macchi V,
Porzionato A, Variola A, Colavito D, Leon A, Guido M, Baldo V, De
Caro R and Bergasa NV: Hepatic expression of endocannabinoid
receptors and their novel polymorphisms in primary biliary
cirrhosis. J Gastroenterol. 45:68–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Poorten D, Shahidi M, Tay E, Sesha
J, Tran K, McLeod D, Milliken JS, Ho V, Hebbard LW, Douglas MW and
George J: Hepatitis C virus induces the cannabinoid receptor 1.
PLoS One. 5:e128412010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moralejo DH, Hansen CT, Treuting P,
Hessner MJ, Fuller JM, Van Yserloo B, Jensen R, Osborne W, Kwitek
AE and Lernmark A: Differential effects of leptin receptor mutation
on male and female BBDR Gimap5-/Gimap5-spontaneously diabetic rats.
Physiol Genomics. 41:9–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dixon JB, Bhathal PS, Hughes NR and
O'Brien PE: Nonalcoholic fatty liver disease: Improvement in liver
histological analysis with weight loss. Hepatology. 39:1647–1654.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bedossa P, Poitou C, Veyrie N, Bouillot
JL, Basdevant A, Paradis V, Tordjman J and Clement K:
Histopathological algorithm and scoring system for evaluation of
liver lesions in morbidly obese patients. Hepatology. 56:1751–1759.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cooper ME and Regnell SE: The hepatic
cannabinoid 1 receptor as a modulator of hepatic energy state and
food intake. Br J Clin Pharmacol. 77:21–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaplan BL: The role of CB1 in immune
modulation by cannabinoids. Pharmacol Ther. 137:365–374. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matias I, Gonthier MP, Orlando P,
Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L,
Festy F, Pasquali R, et al: Regulation, function, and dysregulation
of endocannabinoids in models of adipose and beta-pancreatic cells
and in obesity and hyperglycemia. J Clin Endocrinol Metab.
91:3171–3180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pfefferkorn JA, Guzman-Perez A, Litchfield
J, Aiello R, Treadway JL, Pettersen J, Minich ML, Filipski KJ,
Jones CS, Tu M, et al: Discovery of
(S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)
propanamido) nicotinic acid as a hepatoselective glucokinase
activator clinical candidate for treating type 2 diabetes mellitus.
J Med Chem. 55:1318–1333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Christensen R, Kristensen PK, Bartels EM,
Bliddal H and Astrup A: Efficacy and safety of the weight-loss drug
rimonabant: A meta-analysis of randomised trials. Lancet.
370:1706–1713. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gustavsson C, Yassin K, Wahlström E,
Cheung L, Lindberg J, Brismar K, Ostenson CG, Norstedt G and
Tollet-Egnell P: Sex-different hepatic glycogen content and glucose
output in rats. BMC Biochem. 11:382010. View Article : Google Scholar : PubMed/NCBI
|
